Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BMEA by emailGet an email when BMEA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BMEA, unsubscribe in one click. Privacy
📣 What BMEA Says Is Next
fourth quarter of 2026 · “Both trials include a 26-week primary endpoint, with topline data anticipated in the fourth quarter of 2026.”
Company press release, May 11, 2026 · SEC filing
first quarter of 2027 · “Cash runway projected into the first quarter of 2027 SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026, and provided a business update.”
Company press release, May 11, 2026 · SEC filing
fourth quarter of 2026 · “First patients dosed in the Phase II COVALENT-211 and COVALENT-212 clinical trials of icovamenib in type 2 diabetes (“T2D”); both trials are on track with topline 26-week data expected in the fourth quarter of 2026”
Company press release, May 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full BMEA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BMEA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.